Spots Global Cancer Trial Database for procrit
Every month we try and update this database with for procrit cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia | NCT00495378 | Chemotherapy Cancer Anemia | epoetin alfa | 18 Years - | Ortho Biotech Products, L.P. | |
Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy | NCT01099202 | Leukemia | Procrit (epoeti... | - | M.D. Anderson Cancer Center | |
PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy | NCT00388336 | Anemia Neoplasms | Epoetin Alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS | NCT00656448 | Acute Myelogeno... Myelodysplastic... Leukemia | Procrit | - | M.D. Anderson Cancer Center | |
A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | NCT00446602 | Myelodysplastic... Anemia | Epoetin alfa | 18 Years - 99 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia | NCT00481624 | Anemia | Epoetin Alfa pl... | 18 Years - | University of Louisville | |
PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy | NCT00388336 | Anemia Neoplasms | Epoetin Alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations | NCT00624312 | Cancer | Procrit Placebo | 18 Years - | University of Louisville | |
Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy | NCT00524407 | Chemotherapy Anemia Cancer | Epoetin alfa | 18 Years - | Ortho Biotech Clinical Affairs, L.L.C. |